Assoc. Director, Market Analytics

Does it excite you to work with market analytics and competitive intelligence, and do you have deep experience with U.S. pharmaceutical market data? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.

Your new position As Associate Director, Market Analytics, you will shape our insights agenda for upcoming launches in obesity and rare diseases (petrelintide, SBS, CHI). You will drive comprehensive market analysis and competitive intelligence to inform go-to-market strategy, launch execution, and long-range business planning across our portfolio. You will bring deep expertise in secondary market data analytics and U.S. market dynamics, and act as a strategic thought partner to commercial leadership.

Key Responsibilities

• Drive the usage of secondary data across market research, forecasting support, and competitive intelligence, with emphasis on the U.S. obesity and rare disease markets
• Synthesize data from major providers (IQVIA LAAD/Flexview, NPA/SMART, IPSOS, KOMODO) into actionable market trends and strategic recommendations
• Partner with Commercial, Finance, Market Access, and Forecasting teams to integrate market analytics into strategic plans and revenue modeling
• Present strategic market analytics to executive leadership on market entry, product positioning, and competitive risk
• Translate complex market data into clear, compelling narratives for audiences ranging from senior executives to commercial teams
• Build and maintain dashboards and datasets enabling self-service analytics and visibility into market performance and strategic KPIs

Your Profile

• Bachelor's degree in Business, Marketing, Economics, or a related field; advanced degree (MBA, Master's in Health Economics, or PhD) preferred
• 8-10 years of progressive experience in market research, market analytics, competitive intelligence, or strategic planning within pharma/biotech
• Demonstrated fluency in IQVIA platforms (NPA SMART, LAAD Flexview) and other major data sources (IPSOS, Symphony Health, KOMODO)
• Strong understanding of U.S. healthcare market dynamics, including payer landscape, HCP segmentation, market access, and specialty pharmaceutical channels
• Highly proficient in Excel and PowerPoint; experience with Tableau, Power BI, or SQL is a plus
• Willingness to travel domestically and internationally as needed (approximately 20%)

Salary Range: $158,000 - $218,000/Yr

We are committed to an inclusive recruitment process and welcome applications from all job applicants.

About Zealand Pharma

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late‑stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cabridge, Massachusetts. Learn more at

Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co‑development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.

#J-18808-Ljbffr